People who lost weight with weight-loss drugs such as Mounjaro and Ozempic were found to have a lower risk of obesity-related diseases

A real-world study of about 898,000 U.S. health records found that greater weight loss with GLP-1 receptor agonists was linked to lower risk of obesity-related diseases.

People who lost more weight on drugs such as Ozempic and Mounjaro showed reduced risk of osteoarthritis, chronic kidney disease, sleep apnea, and heart failure.

The findings suggest that the extent of weight loss may help predict future disease risk, reinforcing the importance of continued treatment and weight management.